Novartis AG (NVS) Financials
PeriodQ2 FY2026
Published
Novartis reported net sales of $14.41 billion for Q2 FY2026, the quarter ended June 30, 2026, up 2.5% from a year earlier, though most of that increase came from favorable currency movements; volume growth from medicines such as Kisqali, Kesimpta and Cosentyx outweighed generic competition, chiefly for Entresto and Promacta. Net income attributable to shareholders was $3.26 billion, down 19.2%, and diluted earnings per share were $1.71, against $2.06, while operating income was $4.75 billion, down 2.3%; higher interest expense and a higher tax rate account for most of the wider fall in net income. Net debt was $39.39 billion at June 30, 2026, up 65.6% from a year earlier, after Novartis funded its acquisition of Avidity Biosciences and other deals with cash and new debt.
| Metric | Amount | vs. year ago |
|---|---|---|
| Net sales | $14,408,000,000 | up 2.5% |
| Net income | $3,264,000,000 | down 19.2% |
| Diluted EPS | $1.71 | down 17.0% |
| Operating income | $4,750,000,000 | down 2.3% |
| Net debt | $39,387,000,000 | up 65.6% |
Company details
| Name | Novartis Ag |
|---|---|
| Ticker | NVS |
| CIK | 0001114448 |
| Exchange | NYSE |
| State | Switzerland |
| Incorporation | Switzerland |
| SIC | 2834 |
| Office | Life Sciences |
| Industry | Pharmaceutical Preparations |
| Latest period covered | Q2 FY2026, ended 2026-06-30, 6-K, accession 0001114448-26-000012 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 6-K around 2026-10-27 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included, plus a figure_sources block linking each figure the filing tags to the line that prints it.
- 20-F and 6-K summaryPage Qualitative synthesis of the latest 20-F + 6-K: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 6-K filings and eventsPage Digest of material 6-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Novartis Q2 FY2026
How much revenue did Novartis report in Q2 FY2026?
Novartis reported net sales of $14.41 billion for Q2 FY2026, the quarter ended June 30, 2026, up 2.5% from $14.05 billion in the same quarter a year earlier. Novartis also records smaller other revenues, such as royalties and profit-sharing income, separately from net sales.
What was Novartis net income in Q2 FY2026?
Novartis net income attributable to shareholders was $3.26 billion in Q2 FY2026, down 19.2% from $4.04 billion a year earlier, while operating income was $4.75 billion, down 2.3%. Higher interest expense on increased borrowing and a higher tax rate account for most of the difference.
What were Novartis earnings per share in Q2 FY2026?
Novartis reported diluted earnings per share of $1.71 for Q2 FY2026, the quarter ended June 30, 2026, down 17.0% from $2.06 a year earlier.
How much debt does Novartis have after the Avidity acquisition?
Novartis had net debt of $39.39 billion at June 30, 2026, compared with $23.78 billion a year earlier, after it funded the acquisition of Avidity Biosciences and other deals in the first half with cash and new debt.
Where can I get Novartis AG (NVS) financial data in machine-readable form?
Ticker Scout publishes Novartis AG's financial statements as JSON at https://tickerscout.ai/nvs/financials.json, free, with no API key and no signup. The 20-F and 6-K narrative and the 6-K events digest are published as Markdown at https://tickerscout.ai/nvs/narrative.md and https://tickerscout.ai/nvs/events.md. Novartis AG's SEC CIK is 0001114448. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Novartis AG (NVS) next file with the SEC?
Novartis AG (NVS) is expected to file its next Form 6-K with the SEC on or around October 27, 2026. That date is a projection rather than a company-announced date: it is derived from Novartis AG's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 6-K for Q2 FY2026, the period ended 2026-06-30, SEC accession 0001114448-26-000012.
Related companies
How this page was built
This page was built from Novartis AG's own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.